Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN INC Form 4 January 10, 2003

| FORM 4 | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | | | | | | | |
|----------------------------|------------------------------------|---|--------------------------|--------|--|----------------------------|--|-----------------|--------------------------------|
| | | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of Section 17(a) of the Public Utility Holding Company Act of 1935 Section 30(h) of the Investment Company Act of 1940 | | | | | | | |
| Instruction (Print or Type | | | | | | | | | |
| 1. Name and A | ddress of Repor | ting Person* | 2. Is | suer N | Name AND Tick | er or | Trading Syr | nbol | 6. F |
| Skaletsky | Mark | | | Imn | nunoGen, Inc. | (IMGN |) | | |
| (Last) | (First) | (Middle) | 3. I. Nu Pe | R.S. I | Identification of Reporting if an entity | on 4. | | | |
| 1365 Main S | treet | | | | . | | January 9, | | |
| | (Street) | | | | | 5. | If Amendme Date of Or (Month/Day | ent, riginal | 7. _x_ |
| | MA | 02451 | | | | | | | |
| (City) | (State) | (Zip) | Т | ABLE I | - NON-DERIV | 'ATIVE | | |), DI |
| 1. Title of Security | 2. Trans- 2A. action Date (Month/ | Deemed 3. Execution | Trans- action Code | 8) | . Securities | Acquir l of (D 4 and |) 5) | Secu | riti efici ed Fo Repo |
| | Year) | Year) | Code | | Amount | (A) o | r | (Ins | str. |
| Common Stock | January 9, 2003 | | Α | V | 925 | А | \$3.24 | 7, | 491 |
| Common Stock | January 9, 2003 | | A | v | 967 | A | \$3.10 | 8, | 458 |
| | | | | | | | | | |
| | | | | | | | | | |

Edgar Filing: IMMUNOGEN INC - Form 4

| TABLE | | E SECURITIES ACQ CALLS, WARRANTS, | | | | |
|---|---|--|----------------------|--------------------------------|-----------|---|
| 1. Title of Derivative Security (Instr. 3) | Exercise | 3. Trans- 3A. action Date (Month/ Day/ | Deemed Execution | 4. Transach tion Co (Instr. | - 5 de | Number ative quired posed (Instr |
| | | | | Code V | | (A) |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| 7. Title and Amount of 8 Underlying Securities (Instr. 3 and 4) | Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported | Secu Dire Indi | - | II Be | ature of ndirect eneficia wnership Instr. 4 |

Edgar Filing: IMMUNOGEN INC - Form 4

| | | | (Instr. 4) |
|----------------|----------------------------|----|------------|
| Title | Amount Number Shares | of | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| planation of R | | | |

Transaction(s)

/s/ MARK SKALETSKY January 9, 2003
----**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or i

- * If the form is filed by more than one reporting person, SEE Instruction $4\,(b)\,(v)$.
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.